Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Three Years Earlier in Study MTA26

Trial Profile

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Three Years Earlier in Study MTA26

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 26 Aug 2010 Based in part on this trial, the US FDA has accepted for review a sBLA for Menactra in infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y and W-135, according to a sanofi pasteur media release.
    • 26 Feb 2010 Actual patient number (181) added as reported by ClinicalTrials.gov.
    • 26 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top